- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource
- Language
-
Englisch
- Bibliographic citation
-
EZ-ALBI Score for Predicting Hepatocellular Carcinoma Prognosis ; volume:9 ; number:6 ; year:2020 ; pages:734-743
Liver cancer ; 9, Heft 6 (2020), 734-743
- Creator
-
Kariyama, Kazuya
Nouso, Kazuhiro
Hiraoka, Atsushi
Wakuta, Akiko
Oonishi, Ayano
Kuzuya, Teiji
Toyoda, Hidenori
Tada, Toshifumi
Tsuji, Kunihiko
Itobayashi, Ei
Ishikawa, Toru
Takaguchi, Koichi
Tsutsui, Akemi
Shimada, Noritomo
Kudo, Masatoshi
Kumada, Takashi
- DOI
-
10.1159/000508971
- URN
-
urn:nbn:de:101:1-2020120923285135310917
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:33 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Kariyama, Kazuya
- Nouso, Kazuhiro
- Hiraoka, Atsushi
- Wakuta, Akiko
- Oonishi, Ayano
- Kuzuya, Teiji
- Toyoda, Hidenori
- Tada, Toshifumi
- Tsuji, Kunihiko
- Itobayashi, Ei
- Ishikawa, Toru
- Takaguchi, Koichi
- Tsutsui, Akemi
- Shimada, Noritomo
- Kudo, Masatoshi
- Kumada, Takashi
Other Objects (12)
Newly Developed Modified ALBI Grade Shows Better Prognostic and Predictive Value for Hepatocellular Carcinoma
Adjuvant Immunotherapy after Curative Treatment for Hepatocellular Carcinoma
Durvalumab Plus Tremelimumab: A Novel Combination Immunotherapy for Unresectable Hepatocellular Carcinoma
Selection of Systemic Treatment Regimen for Unresectable Hepatocellular Carcinoma: Does Etiology Matter?
Prioritized Requirements for First-Line Systemic Therapy for Hepatocellular Carcinoma: Broad Benefit with Less Toxicity
Atezolizumab plus Bevacizumab Followed by Curative Conversion (ABC Conversion) in Patients with Unresectable, TACE-Unsuitable Intermediate-Stage Hepatocellular Carcinoma
Combination Immunotherapy with Anti-PD-1/PD-L1 Antibody plus Anti-VEGF Antibody May Promote Cytotoxic T Lymphocyte Infiltration in Hepatocellular Carcinoma, Including in the Noninflamed Subclass
A Novel Treatment Strategy for Patients with Intermediate-Stage HCC Who Are Not Suitable for TACE: Upfront Systemic Therapy Followed by Curative Conversion
Implications of the TACTICS Trial: Establishing the New Concept of Combination/Sequential Systemic Therapy and Transarterial Chemoembolization to Achieve Synergistic Effects
Hepatocellular carcinoma 2009 and beyond : 25 tables
New treatment paradigm with systemic therapy in intermediate-stage hepatocellular carcinoma
Viral hepatitis A to E : an update in 2010 ; 14 tables
Newly Developed Modified ALBI Grade Shows Better Prognostic and Predictive Value for Hepatocellular Carcinoma
Adjuvant Immunotherapy after Curative Treatment for Hepatocellular Carcinoma
Durvalumab Plus Tremelimumab: A Novel Combination Immunotherapy for Unresectable Hepatocellular Carcinoma
Selection of Systemic Treatment Regimen for Unresectable Hepatocellular Carcinoma: Does Etiology Matter?
Prioritized Requirements for First-Line Systemic Therapy for Hepatocellular Carcinoma: Broad Benefit with Less Toxicity
Atezolizumab plus Bevacizumab Followed by Curative Conversion (ABC Conversion) in Patients with Unresectable, TACE-Unsuitable Intermediate-Stage Hepatocellular Carcinoma
Combination Immunotherapy with Anti-PD-1/PD-L1 Antibody plus Anti-VEGF Antibody May Promote Cytotoxic T Lymphocyte Infiltration in Hepatocellular Carcinoma, Including in the Noninflamed Subclass
A Novel Treatment Strategy for Patients with Intermediate-Stage HCC Who Are Not Suitable for TACE: Upfront Systemic Therapy Followed by Curative Conversion
Implications of the TACTICS Trial: Establishing the New Concept of Combination/Sequential Systemic Therapy and Transarterial Chemoembolization to Achieve Synergistic Effects
Hepatocellular carcinoma 2009 and beyond : 25 tables
New treatment paradigm with systemic therapy in intermediate-stage hepatocellular carcinoma
Viral hepatitis A to E : an update in 2010 ; 14 tables
Newly Developed Modified ALBI Grade Shows Better Prognostic and Predictive Value for Hepatocellular Carcinoma
Adjuvant Immunotherapy after Curative Treatment for Hepatocellular Carcinoma
Durvalumab Plus Tremelimumab: A Novel Combination Immunotherapy for Unresectable Hepatocellular Carcinoma
Selection of Systemic Treatment Regimen for Unresectable Hepatocellular Carcinoma: Does Etiology Matter?
Prioritized Requirements for First-Line Systemic Therapy for Hepatocellular Carcinoma: Broad Benefit with Less Toxicity
Atezolizumab plus Bevacizumab Followed by Curative Conversion (ABC Conversion) in Patients with Unresectable, TACE-Unsuitable Intermediate-Stage Hepatocellular Carcinoma
Combination Immunotherapy with Anti-PD-1/PD-L1 Antibody plus Anti-VEGF Antibody May Promote Cytotoxic T Lymphocyte Infiltration in Hepatocellular Carcinoma, Including in the Noninflamed Subclass
A Novel Treatment Strategy for Patients with Intermediate-Stage HCC Who Are Not Suitable for TACE: Upfront Systemic Therapy Followed by Curative Conversion
Implications of the TACTICS Trial: Establishing the New Concept of Combination/Sequential Systemic Therapy and Transarterial Chemoembolization to Achieve Synergistic Effects
Hepatocellular carcinoma 2009 and beyond : 25 tables
New treatment paradigm with systemic therapy in intermediate-stage hepatocellular carcinoma